Exploring knee replacement alternatives including MSC therapy, PRP, and viscosupplementation. Evidence-based guide for patients weighing regenerative options before surgery.
For patients with moderate-to-severe knee osteoarthritis, several non-surgical options exist alongside — and in some cases before — total knee replacement. These include mesenchymal stem cell (MSC) therapy, platelet-rich plasma (PRP), hyaluronic acid injections, and structured physiotherapy programmes. None of these is a guaranteed substitute for surgery in advanced disease, but for appropriate patients they may significantly reduce pain, improve function, and delay or potentially avoid the need for an operation. The key word is 'appropriate' — eligibility depends on the severity of joint damage, age, weight, activity level, and realistic expectations.
Knee osteoarthritis is primarily a disease of articular cartilage — the smooth, shock-absorbing tissue covering the ends of the bones. Cartilage has almost no blood supply, which is why it heals so poorly. Once damaged, chondrocytes (the cells that maintain cartilage) cannot reliably rebuild what's lost. Over time, the cartilage thins or disappears entirely, bone rubs against bone, and the synovium — the joint lining — becomes chronically inflamed. That inflammation then accelerates further cartilage loss. It's a self-reinforcing cycle.
Mesenchymal stem cells — particularly umbilical cord-derived MSCs — work primarily through paracrine signalling. That means rather than physically becoming new cartilage themselves, these cells release bioactive molecules that influence the local tissue environment. The signals include growth factors such as TGF-β (transforming growth factor beta) and VEGF (vascular endothelial growth factor), anti-inflammatory cytokines that downregulate IL-1β and TNF-α, and extracellular vesicles that carry molecular instructions to neighbouring cells.
The evidence base for MSC therapy in knee osteoarthritis is one of the more developed areas within regenerative medicine. This is not a speculative or fringe treatment — it has been studied in registered clinical trials across multiple countries over more than a decade.
Honest medicine requires stating what we don't know — and for MSC therapy in knee OA, several important uncertainties remain.
Not every patient with knee pain is a candidate. And not every patient who wants to avoid surgery can reasonably do so. A responsible assessment looks at several factors simultaneously.
This is one of the most common questions international patients ask — and it deserves a direct, honest answer.
Our medical team follows a structured, assessment-first approach. No patient is offered MSC therapy without a clinical review of their specific joint condition, imaging, and overall health status. This is both medically responsible and practically necessary — the treatment protocol varies significantly between patients.
The quality of the cell product matters as much as the clinical indication. MSCs used in our protocols are derived from ethically donated umbilical cord tissue — specifically Wharton's jelly, which yields a consistently rich MSC population with minimal donor site morbidity. Cells are cryopreserved at -196°C in GMP-aligned processing conditions and undergo identity verification via surface markers CD73, CD90, and CD105. Each batch is screened for HIV, HBV, HCV, CMV, EBV, mycoplasma, and endotoxins before clinical use.
Managing expectations is not a disclaimer — it's core clinical care. Patients who understand what realistic improvement looks like are better positioned to evaluate whether treatment has worked and to make informed decisions about next steps.
MSC intra-articular injection carries a defined, manageable risk profile when performed in a regulated clinical setting with quality-controlled cell products. Common and expected effects include post-injection joint swelling and discomfort for 24–72 hours — this is a normal inflammatory response and generally self-limiting. Temporary stiffness is also common.
Regenerative approaches are not the right choice in every situation. This is important to say clearly. Total knee replacement has strong, decades-long outcome data in advanced disease. For patients with Grade 4 OA, significant joint deformity, or failed prior conservative care over years, surgery offers a level of reliable, durable pain relief and function restoration that regenerative medicine cannot currently match at scale.
Patients travelling from the UK, US, Australia, Europe, and across Asia typically stay 3–5 days for a single orthopaedic MSC session. The first day is assessment and protocol finalisation. The treatment session itself is outpatient and takes 1–2 hours. One to two rest and monitoring days follow before travel. English-speaking patient coordinators manage pre-arrival documentation, clinic appointments, and post-discharge communication. Remote follow-up at 1, 3, and 6 months is coordinated in collaboration with your home physician, who should receive a full clinical summary.
No — and any clinic suggesting otherwise should be questioned. MSC therapy is a biologically rational, evidence-informed option for selected patients with moderate osteoarthritis who want to delay or potentially avoid surgery. It is not a universal substitute for knee replacement. It is not appropriate for all stages of disease. And it is not a guaranteed outcome for any patient, regardless of age, disease stage, or cell product quality. What it offers — for the right patient, with the right expectations — is a meaningful regenerative option within a comprehensive, physician-led care plan.
Safety depends on the cell source, preparation quality, administration technique, patient selection, and clinical oversight. Allogeneic umbilical cord MSC injections performed at a regulated clinic with GMP-processed cells have shown a favourable short-to-medium term safety profile across multiple published trials. Serious adverse events are rare, though not impossible. The most important safety variable is not the cells themselves — it is whether the clinic has properly screened the patient, uses quality-documented cell products, and has a clear protocol for managing any post-procedure concerns. An unregulated offer promising guaranteed results is a fundamentally different risk category from a physician-supervised, clinically indicated procedure.
Most orthopaedic MSC protocols involve 1–3 intra-articular sessions, depending on disease severity, the patient's response to initial treatment, and the specific protocol design. Some patients receive a single injection as a starting point, with reassessment at 3–6 months before deciding whether a second session adds further benefit. More aggressive disease or bilateral involvement may support a multi-session approach from the outset. There is no universal answer — protocol design is part of the clinical assessment, not a fixed package.
Bone marrow aspirate concentrate (BMAC) and umbilical cord-derived MSC therapy are both regenerative approaches, but they are different products with different evidence profiles and different patient experiences. BMAC requires a painful harvest procedure from the patient's own pelvis and yields a heterogeneous cell population that varies significantly between donors. Umbilical cord MSCs are allogeneic, require no harvest procedure, are processed to a consistent clinical grade, and have a defined cell identity. Neither approach has been proven superior in a large head-to-head trial — but the consistency and quality-control advantages of GMP-processed allogeneic MSCs are a practical argument for many patients, particularly older adults or those with comorbidities that complicate autologous harvest.
That is more common than you might expect — and it doesn't necessarily mean the treatment is fringe or unproven. Regenerative orthopaedics sits at the intersection of two specialities that have historically operated separately: joint surgery and cell biology. Many orthopaedic surgeons are familiar with PRP (which is now mainstream in many countries) but less familiar with MSC-based protocols, which are more recent at clinical scale. A well-informed second opinion from a physician who specialises in regenerative medicine, combined with transparent sharing of your treatment plan with your home surgeon, is a responsible way to bridge that gap.
This requires individual clinical review. Many common pain medications — including NSAIDs like ibuprofen and naproxen — have anti-platelet and anti-inflammatory effects that may theoretically interfere with the post-injection inflammatory cascade that supports MSC engraftment and signalling. Corticosteroid injections within 4–6 weeks of a planned MSC session are typically avoided for similar reasons. Your treating physician will review your current medication list as part of the pre-treatment assessment and provide specific guidance. Do not discontinue any prescribed medication without consulting your prescribing doctor.
If you're weighing alternatives to knee replacement, the most responsible starting point is an honest clinical assessment — not a commitment to any particular treatment path. Our medical team reviews your imaging, diagnosis, treatment history, and overall health to determine whether MSC therapy is a realistic option for your specific situation, and if so, what a personalised protocol would involve. Consultations are free, and there is no obligation to proceed.
Knee Replacement Alternatives in 2026: What Stem Cell Therapy Can and Cannot Offer